Go to Patients & Caregivers Site
Customer Contact Center:
1-888-PLMZYME (756-9963)

Indication Statement:

Daily administration of Pulmozyme (dornase alfa) in conjunction with standard therapies is indicated in the management of cystic fibrosis (CF) patients to improve pulmonary function. In patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics. Safety and efficacy of daily administration have not been demonstrated in patients for longer than twelve months.

Important Safety Information

  • Pulmozyme should not be used in patients with known hypersensitivity to dornase alfa, or any ingredients of the product.
  • Pulmozyme should be used in conjunction with standard therapies for CF.
  • Most common reported adverse events associated with the use of Pulmozyme include: voice alteration, pharyngitis, laryngitis, rash, chest pain, and conjunctivitis.
Reimbursement

Reimbursement

Making Pulmozyme accessible to patients

Genentech® has been providing support to the cystic fibrosis community for over 17 years. We strive to help eligible patients obtain Pulmozyme® regardless of their ability to pay.

Pulmozyme Access Solutions®. This program helps resolve access and reimbursement issues for individual patients every day. Our in-house dedicated Specialists help bring patient treatment and practice solutions together.
Learn more ›

Pulmozyme Co-Pay Card Program. Pulmozyme Access Solutions offers the Pulmozyme Co-Pay Card Program to help qualified patients with the out-of-pocket (OOP) costs associated with their Pulmozyme prescription.
Learn more ›

To speak live with an Access Solutions Specialist about these assistance resources, call 1-800-690-3023 from 6AM-5PM PT, Monday to Friday.

Fax: 1-800-963-1792
Web: www.PulmozymeAccessSolutions.com

Next:
Pulmozyme Access Solutions ›